|
Dr. van Duzer served most recently as Vice President of Manufacturing at ActivBiotics, a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of inflammatory diseases and bacterial infections. John worked to advance the product in preparation from Phase I to ready for product launch. Dr. van Duzer joined ActivBiotics in November 2002 as Director of Medicinal Chemistry. Prior to joining ActivBiotics, John served as the Director of Chemistry at Inotek Corporation, a clinical-stage, drug development company. Prior to joining Inotek, Dr. van Duzer worked as a medicinal chemist in the Arthritis and Bone Metabolism research group of Ciba-Geigy and later Novartis for twelve years where he was responsible for the invention of lumiracoxib, a novel COX-2 inhibitor currently sold in a number of countries. He received his BA in Chemistry from the University of Pennsylvania and his Ph.D. in Organic Chemistry from Yale University. | 